UK’s CMA Doubles Down On Liothyronine Objections
Following Ruling On Unfair Pricing For Phenytoin In March
Executive Summary
The UK’s CMA has reiterated its belief that Advanz Pharma charged excessive and unfair prices for liothyronine in the UK, following a separate ruling that provided detailed guidance on how such matters should be evaluated.
You may also be interested in...
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
Advanz Pharma Agrees Sale In Largest European Deal Since COVID-19 Pandemic
Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.